DXR
Bargain BinDaxor Corporation · Healthcare · United States · $54M cap · $106K/day traded
$8.52 -0.1% · close 11 Nov · scored 12 Nov
Bargain Bin: Looks like a bargain; the quality and the trend say why it is in the bin.
As of 12 Nov 2026, the MoatMap Score for Daxor Corporation (DXR) is 36/100, ranked against 25,000+ stocks in 38 markets (Quality 45, Value 50, Momentum 32, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT DAXOR CORPORATION
Read
Daxor Corporation is a medical instrumentation and biotechnology company specializing in blood volume measurement technology. The company's competitive moat is anchored by its BVA-100 (Blood Volume Analyzer), which is the only FDA-cleared diagnostic device capable of directly and accurately measuring a patient's total blood volume. Daxor operates as a unique niche player, with its technology increasingly adopted in intensive care units to guide fluid management for heart failure and sepsis patients.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 6.3M | 1.3M | 2.1M | 10.3M | 17.8% | — | 9.3M | 16.4M | 26.2% |
| EPS | — | 0.87 | 0.14 | -0.09 | 1.64 | 23.5% | 1.10 | — | — | — |
| Shares | — | 4.3M | 4.8M | 4.9M | 5.1M | +17.9% | 5.8M | — | — | — |
| Debt | 3.0M | 1.2M | 0.8M | 0.7M | — | -37.7% | — | — | — | — |
| Equity | — | 29.0M | 34.0M | 35.8M | 45.9M | 16.6% | — | — | — | — |
| Op CF | — | -0.8M | -3.7M | 25.7K | 0.6M | 2122.2% | -8.2M | — | — | — |
| Inv CF | — | — | — | — | — | — | — | — | — | — |
| Fin CF | — | 58.6K | 3.7M | -25.7K | -0.6M | — | — | — | — | — |
Made a new 52-week low 2 trading days ago, 42% below its 52-week high. The fall has not stopped yet.
Swung more than 55% of stocks we rank over the past year (volatility 45% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DXR are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| DXR | Daxor Corporation(you) | $54M | 36 |
| POCI | Precision Optics Corporation, Inc. | $52M | 35 |
| KRMD | KORU Medical Systems, Inc. | $146M | 35 |
| OSUR | OraSure Technologies, Inc. | $285M | 42 |
| STXS | Stereotaxis, Inc. | $102M | 7 |
| ANGO | AngioDynamics, Inc. | $520M | 35 |
| SMTI | Sanara MedTech Inc. | $301M | 61 |
| STAA | STAAR Surgical Company | $1.1B | 33 |
| KMTS | Kestra Medical Technologies, Ltd. | $1.7B | 31 |
| AZTA | Azenta, Inc. | $1.6B | 48 |
Peer medians: ROE -31.0% · P/E 26.3x · Gross margin 62.7%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.